Income statement
USD
Annual
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|
| Revenue | 167M | 156M | 111M | 56M | 62M |
| Gross Profit | 143M | 132M | 90M | 40M | 42M |
| Operating Income | 37M | 33M | 4M | -24M | -29M |
| EBITDA | 45M | 40M | 13M | -18M | 4M |
| Net Income | 85M | 26M | -15M | -34M | 5M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.04
-25.00% today
1Y Change
—
Window
No data
Historical coverage is still loading
We are still backfilling 1Y daily history for this symbol. Some charts may stay empty until more data arrives.
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
BioDelivery Sciences Intl, Inc. Wrrt (BDSIW) is a Healthcare stock. The stock last traded around $0.04. Baseline metrics include revenue growth of +6.5%, EPS growth of +215.4%, a dividend yield of 0.0%. What stands out right now is revenue +6.5%, EPS +215.4%, free cash flow +62.7% with operating margin 22.3% and ROIC 15.0%. Valuation is more restrained than many high-expectation growth names at P/E 6.8 and price/sales 3.5. Stock Foundry combines BDSIW price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
BDSIW
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
BDSIW Max Drawdown
—
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for BDSIW and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$62.0M
+11.4% YoY
FY Net Income
$5.3M
+115.6% YoY
Free Cash Flow
-$38.3M
-46.4% YoY
Revenue Growth
+6.5%
EPS Growth
+215.4%
Gross Margin
86.0%
Net Margin
50.9%
Income statement
USD
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|
| Revenue | 167M | 156M | 111M | 56M | 62M |
| Gross Profit | 143M | 132M | 90M | 40M | 42M |
| Operating Income | 37M | 33M | 4M | -24M | -29M |
| EBITDA | 45M | 40M | 13M | -18M | 4M |
| Net Income | 85M | 26M | -15M | -34M | 5M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|
| Cash & Equivalents | 114M | 112M | 64M | 44M | 21M |
| Total Assets | 325M | 240M | 183M | 109M | 88M |
| Total Liabilities | 137M | 132M | 113M | 79M | 79M |
| Shareholder Equity | 188M | 108M | 70M | 30M | 9M |
| Total Debt | 59M | 78M | 59M | 52M | 48M |
| Net Debt | -56M | -33M | -5M | 8M | 26M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
32M
-34.6% YoY
Capital Expenditures
6M
-184.2% YoY
Free Cash Flow
38M
-46.4% YoY
Key ratios
Gross Margin
86.0%
Operating Margin
22.3%
Net Margin
50.9%
ROE
57.3%
Debt / Equity
0.31x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.